Latest News

(UroToday.com) Upper tract urothelial carcinoma (UTUC) is a relatively rare malignancy, comprising a small subset of urothelial disease. Compared to bladder cancer, endoscopic management of UTUC and intraluminal therapy is substantially more difficult. As a result, organ-preserving treatments are technically difficult. Thus, these approaches are often reserved for easily accessible, small, low-grade tumors. However, novel approaches […]

(UroToday.com) The Society of Urologic Oncology session at the 2021 Virtual AUA annual meeting’s bladder cancer session included a presentation by Dr. Peter Black discussing what is new for biomarkers in bladder cancer. Dr. Black highlighted that there are different types of biomarkers based on the disease state of interest: Non-muscle invasive bladder cancer (NMIBC): urine […]

(UroToday.com) Upper tract urothelial carcinoma (UTUC) is a relatively rare malignancy, comprising a small subset of urothelial disease. The diagnosis of UTUC is often delayed as a result of vague, non-specific, or absent symptoms until significant disease progression. Further, compared to bladder cancer, endoscopic diagnosis, and management of UTUC is substantially more difficult which makes diagnosis […]

(UroToday.com) Upper tract urothelial carcinoma (UTUC) is a relatively rare malignancy, comprising a small subset of urothelial disease. Compared to bladder cancer, endoscopic management of UTUC and intraluminal therapy is substantially more difficult. As a result, organ-preserving treatments are technically difficult. Thus, these approaches are often reserved for easily accessible, small, low-grade tumors. In part due […]

(UroToday.com) As a follow-up to the JAVELIN BLADDER 100 trial,1 which demonstrated the efficacy of avelumab as first-line maintenance therapy for patients with advanced urothelial carcinoma who have NOT progressed on first-line platinum-based chemotherapy, Dr. Bellmunt and colleagues herein report post hoc analyses in previously unreported clinical and genomic subgroups.

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with BCG is guideline-recommended on the basis of proven benefits in disease recurrence. In contrast, for those with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG IR NMIBC), the […]

(UroToday.com) In this analysis by Andrew Salib and colleagues, the authors explore on a larger scale the risk of developing secondary malignancies after pelvic radiation therapy for a primary pelvic malignancy (rectal/anal, bladder, prostate, uterine, cervical). While confirming that radiation treatment for pelvic malignancies increases the risk of developing secondary malignancies over the patient’s lifetime, […]

(UroToday.com) As a follow-up to the JAVELIN BLADDER 100 trial,1 which demonstrated the efficacy of avelumab as a first line maintenance therapy for patients with advanced urothelial carcinoma who have NOT progressed on first line platinum based chemotherapy, Dr. Bellmunt and colleagues herein report a secondary analysis of time to end of next-line therapy in patients […]

(UroToday.com) At the plenary session of the AUA 2021 virtual annual meeting, Dr. Alejandro Rodriguez provided the Confederacion Americana de Urologia (CAU) lecture discussing controversies and challenges of penile cancer management.

(UroToday.com) The bladder cancer session at the Society of Urologic Oncology’s (SUO) program at the AUA 2021 virtual annual meeting included a presentation by Dr. Scott Gilbert who discussed the quality of life after cystectomy and urinary diversions. Dr. Gilbert started by defining health-related quality of life: